clinical trial · NCT06810960
A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease
Eisai Korea Inc.·—·recruiting·n = 3,000
Alzheimer's DiseaseNo Intervention
brief summary
The primary purpose of this study is to evaluate safety of LEQEMBI in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in patients treated with LEQEMBI.
started
Feb 24, 2025
primary completion
Sep 30, 2029
completion
Sep 30, 2029
last updated
Apr 21, 2026
official title
A 6-Year Postmarketing Safety and Clinical Outcome Study of LEQEMBI® in the Treatment of Alzheimer's Disease Using Real-World Data From South Korean Patients Enrolled Into the South Korean JOint RegistrY for ALZheimer's Treatment and Diagnostics (JOY-ALZ) Registry
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol